Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis

Journal article

Publication Details

Author(s): Kürten S, Jackson LJ, Kaye J, Vollmer TL
Journal: Cns Drugs
Publication year: 2018
Volume: 32
Journal issue: 11
Pages range: 1039-1051
ISSN: 1172-7047


Growing evidence indicates that B cells play a key role in the pathogenesis of multiple sclerosis (MS). B cells occupy distinct central nervous system (CNS) compartments in MS, including the cerebrospinal fluid and white matter lesions. Also, it is now known that, in addition to entering the CNS, B cells can circulate into the periphery via a functional lymphatic system. Data suggest that the role of B cells in MS mainly involves their in situ activation in demyelinating lesions, leading to altered pro- and anti-inflammatory cytokine secretion, and a highly effective antigen-presenting cell function, resulting in activation of memory or naïve T cells. Clinically, B cell-depleting agents show significant efficacy in MS. In addition, many disease-modifying therapies (DMTs) traditionally understood to target T cells are now known to influence B cell number and function. One of the earliest DMTs to be developed, glatiramer acetate (GA), has been shown to reduce the total frequency of B cells, plasmablasts, and memory B cells. It also appears to promote a shift toward reduced inflammation by increasing anti-inflammatory cytokine release and/or reducing pro-inflammatory cytokine release by B cells. In the authors' opinion, this may be mediated by cross-reactivity of B cell receptors for GA with antigen (possibly myelin basic protein) expressed in the MS lesion. More research is required to further characterize the role of B cells and their bidirectional trafficking in the pathogenesis of MS. This may uncover novel targets for MS treatments and facilitate the development of B cell biomarkers of drug response.

FAU Authors / FAU Editors

Kürten, Stefanie Prof. Dr. med.
Lehrstuhl für Anatomie und Zellbiologie

External institutions with authors

Teva Pharmaceutical Industries Ltd.
University of Colorado System

How to cite

Kürten, S., Jackson, L.J., Kaye, J., & Vollmer, T.L. (2018). Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis. Cns Drugs, 32(11), 1039-1051.

Kürten, Stefanie, et al. "Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis." Cns Drugs 32.11 (2018): 1039-1051.


Last updated on 2019-18-07 at 07:20